FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology, rehabilitation, clinical laboratory diagnostics and therapy. Patient is examined for the biochemical marker oncostatin M (OSM) in the blood serum with acute MI on the first day of the disease. If the OSM level is more than 18.40 ng/ml, the probability of developing unfavorable heart LV remodeling is considered to be high.
EFFECT: method enables high-accuracy detection of a high-risk group of developing unfavorable heart LV remodeling in patients with acute STEMI for dispensary observation, and assessing a personal risk of progression of LV remodeling.
1 cl, 2 ex
Authors
Dates
2022-04-15—Published
2021-10-27—Filed